ARWR ARROWHEAD PHARMACEUTICALS, ...

Nasdaq arrowheadpharma.com


$ 39.36 $ -1.74 (-4.22 %)    

Wednesday, 19-Nov-2025 14:32:26 EST
QQQ $ 596.31 $ -0.75 (-0.13 %)
DIA $ 459.79 $ -1.65 (-0.36 %)
SPY $ 659.49 $ -1.30 (-0.2 %)
TLT $ 89.11 $ -0.11 (-0.13 %)
GLD $ 374.42 $ -3.35 (-0.89 %)
$ 40.47
$ 41.06
$ 39.31 x 106
$ 39.40 x 5
$ 39.22 - $ 41.17
$ 9.57 - $ 43.69
2,960,691
na
5.6B
$ 1.69
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 02-10-2025 12-31-2024 10-Q
4 11-26-2024 09-30-2024 10-K
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 02-06-2024 12-31-2023 10-Q
8 11-29-2023 09-30-2023 10-K
9 08-07-2023 06-30-2023 10-Q
10 05-02-2023 03-31-2023 10-Q
11 02-06-2023 12-31-2022 10-Q
12 11-28-2022 09-30-2022 10-K
13 08-04-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 02-02-2022 12-31-2021 10-Q
16 11-22-2021 09-30-2021 10-K
17 08-05-2021 06-30-2021 10-Q
18 05-04-2021 03-31-2021 10-Q
19 02-04-2021 12-31-2020 10-Q
20 11-23-2020 09-30-2020 10-K
21 08-05-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 02-05-2020 12-31-2019 10-Q
24 11-25-2019 09-30-2019 10-K
25 08-05-2019 06-30-2019 10-Q
26 05-08-2019 03-31-2019 10-Q
27 02-07-2019 12-31-2018 10-Q
28 12-11-2018 09-30-2018 10-K
29 08-07-2018 06-30-2018 10-Q
30 05-08-2018 03-31-2018 10-Q
31 02-09-2018 12-31-2017 10-Q
32 12-12-2017 09-30-2017 10-K
33 08-03-2017 06-30-2017 10-Q
34 05-03-2017 03-31-2017 10-Q
35 02-06-2017 12-31-2016 10-Q
36 12-14-2016 09-30-2016 10-K
37 08-09-2016 06-30-2016 10-Q
38 05-10-2016 03-31-2016 10-Q
39 02-09-2016 12-31-2015 10-Q
40 12-14-2015 09-30-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 rbc-capital-maintains-outperform-on-arrowhead-pharma-raises-price-target-to-52

RBC Capital analyst Luca Issi maintains Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and raises the price target from $4...

 chardan-capital-maintains-buy-on-arrowhead-pharma-maintains-60-price-target

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 price target.

 piper-sandler-maintains-overweight-on-arrowhead-pharma-raises-price-target-to-70

Piper Sandler analyst Edward Tenthoff maintains Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and raises the price target...

 fda-clears-arrowhead-pharmas-first-ever-home-injection-for-rare-fat-disorder

Arrowhead Pharmaceuticals won FDA approval for Redemplo (plozasiran), an siRNA drug reducing high triglycerides in adults with ...

 arrowhead-pharmaceuticals-receives-fda-approval-of-redemplo-to-reduce-triglycerides-in-adults-with-familial-chylomicronemia-syndrome

https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025

 morgan-stanley-maintains-equal-weight-on-arrowhead-pharma-raises-price-target-to-45

Morgan Stanley analyst Michael Ulz maintains Arrowhead Pharma (NASDAQ:ARWR) with a Equal-Weight and raises the price target ...

 crispr-therapeutics-investigational-gene-therapy-shows-promising-lipid-lowering-effects-in-early-trial

CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its...

 hc-wainwright--co-reiterates-buy-on-arrowhead-pharma-maintains-80-price-target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $80 p...

 arrowhead-pharmaceuticals-files-to-begin-phase-12a-trial-for-dual-target-rnai-drug-aro-dimer-pa-aims-to-treat-atherosclerotic-cardiovascular-disease-from-mixed-hyperlipidemia

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has filed a request for regulatory clearance to initiate ...

 4-biotechnology-stocks-that-outshine-in-momentum-amid-strong-technicals

Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week ...

 arrowhead-pharma-files-request-for-regulatory-clearance-to-initiate-phase-12a-clinical-trial-of-aro-mapt-investigational-rnai-therapeutic-for-tauopathies

 - In preclinical studies presented today at the RNA Leaders USA Congress 2025, investigational ARO-MAPT demonstrated potent an...

 hc-wainwright--co-reiterates-buy-on-arrowhead-pharma-maintains-80-price-target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $80 p...

Core News & Articles

Upon closing, Arrowhead will receive an upfront payment of $200 millionNovartis will receive an exclusive worldwide license to ...

Core News & Articles

- Arrowhead has elected to receive approximately $50 million worth of Arrowhead common stock from Sarepta, which will be placed...

 chardan-capital-maintains-buy-on-arrowhead-pharma-maintains-60-price-target

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION